Google Search

Search

Already a Member ?

Best Business Opportunities in Benin, Africa - Identification and Selection of right Project, Thrust areas for Investment, Industry Startup and Entrepreneurship Projects

Why Reasons to Start A Business in Benin

For foreign exchange revenues, GDP is mostly geared toward export. Marble, limestone, and salt are examples of other natural resources. Benin's significant industries include: Agriculture, mining, manufacturing, and tourism are some of Benin's key sectors. Agriculture generates more than half of GDP and employs 80% of the workforce. Cotton, cocoa beans (the world's largest producer), cassava (the world's largest producer), rice (the world's third-largest producer), and corn are all major crops farmed in Benin. Benin's biggest exports include: Coffee, cocoa beans, palm kernels, cotton lint, and rubber are among Benin's top exports. You must have a strong entrepreneurial spirit and be willing to work hard to start a business in Benin. You'll also require good communication skills and a decent command of the French or English languages, as they are the two most commonly used languages.

 

What are The Natural Resources in Benin?

Manganese, limestone, marble, and phosphates are among Benin's natural resources. Many of these minerals can be found in the country's beaches and at its border with Burkina Faso (which has manganese mines). In fact, France purchased practically all of its manganese from within its boundaries during colonial times (when it was known as Dahomey). Still, there are a lot of unexplored potentials, particularly in terms of offshore oil reserves, and discoveries might help enhance exports and fuel development. Benin, for example, has made great progress in its oil sector, with growth rates increasing dramatically in recent years as a result of these efforts.

 

What are The Business Opportunities in Benin?

Entrepreneurs will find Benin to be a stimulating environment. The economy of the country has developed dramatically in recent years, with a GDP growth rate of over 7%. Before starting a business in Benin, you should be aware of some of the most prevalent business concerns. If you're thinking about starting your own business but haven't considered Benin, you should reconsider. Now is a perfect moment to start a business in Benin, with an effective government that is always working to make its economy more conducive for foreign business owners and a low-to-no taxes structure that makes it inexpensive for new firms. Many foreign corporations have recently established operations there, owing to the country's stable political and economic climate.One of the most significant advantages is, of course, the absence of tax. Benin does not have a government. Personal and corporate income taxes are not common in African countries. This means you'll only have to pay taxes on products and services imported from outside of Africa, as well as a 0.15 percent export tax (0.30 percent if you sell oil). Furthermore, Benin has no sales taxes, which means your company will be able to keep more of what it earns. Is there any other benefit? In comparison to other countries, the cost of doing business in Benin is fairly low. For example, office space can be rented for as little as $50 per month, which is significantly less than what you could expect to pay elsewhere. Similarly, utilities are generally inexpensive. Benin is an excellent spot to establish a business because of all of these qualities.

 

What Businesses are Successful in Benin?

Are the most popular enterprises in Benin manufacturing successful? First and foremost, what kind of company do you want to start? What is the location of your target market? What kind of competition are we talking about? What are the materials you'll need to get started? These questions may appear daunting, but they're all important bits of information that can help you frame your response. While there is no one-size-fits-all approach that will work for everyone, the following procedures should be helpful: First and foremost, choose the type of company you want to start. Do you have a special interest or skill? Is there a preference in Benin for particular items or services over others? It's time to perform some research once you've decided on a course of action. Personal and corporate income taxes are not common in African countries. This means you'll only have to pay taxes on products and services imported from outside of Africa, as well as a 0.15 percent export tax (0.30 percent if you sell oil). Furthermore, Benin has no sales taxes, which means your company will be able to keep more of what it earns. Is there any other benefit? In comparison to other countries, the cost of doing business in Benin is fairly low. For example, office space can be rented for as little as $50 per month, which is significantly less than what you could expect to pay elsewhere. Similarly, utilities are generally inexpensive. Benin is an excellent spot to establish a business because of all of these qualities.

 

Is Benin Good for Business?

As you may know, starting and running a business is difficult, but those considering investing in Benin could rest assured that it is one of Africa's most lively and fastest-growing economies. For example, real GDP increased by 5.4 percent year over year in 2015. Since 2011, this has been notably true. Economic reforms in Benin have also aided growth, with private-sector progress attracting foreign investment from nations such as France and South Korea. But what is it about Benin that makes it so appealing? Here are five reasons why investors might consider Benin as a potential investment:

 

1. The economy of the country is expanding at a rapid pace. Since 2011, real GDP has increased at an annual rate of 4.7 percent on average (source: IMF). In the years 2014 and 2015 That figure was 5.4 percent on its own (source: IMF).

2. It is a democratic country with well-established political structures and procedures.

 

Business-Friendly Policies and Government Initiatives;

In Benin, you can start your own business. Obtain all essential licences and permissions, including a tax identification number and the registration of your business name. Make sure you pay your taxes on time. Form a partnership or firm with at least one other individual. If appropriate, register for VAT. If you want to open a bank account outside of Benin, you'll need an International Bank Account Number (IBAN). Find out about any labour laws that may apply to your company. Find out about zoning restrictions in your area that may effect where you can open a store. Market research will help you figure out who your clients are and what they want from your product or service. Investigate any local competitors who may be operating in the area so that you may set yourself apart by providing something unique.

 

Benin's Industrial Infrastructure;

The development of industrial infrastructure has been on Benin's agenda for years, thanks to funding from a variety of local and international financial organisations. With train service and four main ports (Porto-Novo, Cotonou, Porto-Paix, and Parakou) connected to regional trade pathways throughout West Africa and beyond, the country has rather good transportation linkages. Through railways, roads, bridges, and pipelines, Benin is connected to regional powerhouses Nigeria, Cote d'Ivoire, and Ghana.

 

What are The Steps for Starting a Business in Benin?

The development of industrial infrastructure has been on Benin's agenda for years, thanks to funding from a variety of local and international financial organisations. With train service and four main ports (Porto-Novo, Cotonou, Porto-Paix, and Parakou) connected to regional trade pathways throughout West Africa and beyond, the country has rather good transportation linkages. Through railways, roads, bridges, and pipelines, Benin is connected to regional powerhouses Nigeria, Cote d'Ivoire, and Ghana.

 

Industrial Growth in Benin

In 2015, the industrial sector, which was dominated by food and drinks, accounted for more than 22% of total GDP. The country's biggest industries are beverages (primarily beer), cotton textiles, and cement. Food processing, tobacco products, transportation equipment, paper goods, leather products, and chemicals are all prominent manufacturing businesses. Benin imports the majority of its manufactured goods from other African countries or France, as well as about 40% of its grain requirements. Benin exports fabric throughout Africa and Europe as one of West Africa's leading textile producers. Yams, cassava, peanuts, and corn are all important crops in the country. It also produces rubber and cocoa beans. Despite these natural riches, agriculture only contributes roughly 10% of GDP

 

Market Size of Benin

Benin has a population of 9.4 million people and a GDP per capita of $2,900, according to World Bank data.

Cocoa beans, cotton, groundnuts, and other foodstuffs are the country's principal exports.

It imports consumer products as well as capital goods such as automobiles and industrial machinery.

For the first five years, foreign investors can benefit from Benin's 0 percent corporate tax rate for manufacturing enterprises. Benin's government provides additional incentives to companies who export at least 50% of their output.

We can provide you detailed project reports on the following topics. Please select the projects of your interests.

Each detailed project reports cover all the aspects of business, from analysing the market, confirming availability of various necessities such as plant & machinery, raw materials to forecasting the financial requirements. The scope of the report includes assessing market potential, negotiating with collaborators, investment decision making, corporate diversification planning etc. in a very planned manner by formulating detailed manufacturing techniques and forecasting financial aspects by estimating the cost of raw material, formulating the cash flow statement, projecting the balance sheet etc.

We also offer self-contained Pre-Investment and Pre-Feasibility Studies, Market Surveys and Studies, Preparation of Techno-Economic Feasibility Reports, Identification and Selection of Plant and Machinery, Manufacturing Process and or Equipment required, General Guidance, Technical and Commercial Counseling for setting up new industrial projects on the following topics.

Many of the engineers, project consultant & industrial consultancy firms in India and worldwide use our project reports as one of the input in doing their analysis.

We can modify the project capacity and project cost as per your requirement.
We can also prepare project report on any subject as per your requirement.

Page 11 of 54 | Total 531 projects in this category
« Previous   Page 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 .... 53 54   Next »

Add multiple items to inquiry
Select the items and then press Add to inquiry button

Select all | Clear all Sort by

Lithium Ion Battery (Battery Assembly)

Lithium-ion batteries are all about the movement of lithium ions: the ions move one way when the battery charges (when it's absorbing power); they move the opposite way when the battery discharges (when it's supplying power): Lithium batteries are now powering a wide range of electrical and electronical devices, including laptop computers, mobile phones, power tools, telecommunication systems and new generations of electric cars and vehicles. The high cost, associated with batteries that are used in the electric vehicles, is considered to be critical for India's ambitious target. To counter this, the Government of India is planning to set up lithium-ion battery manufacturing units in India, aggressively. The Indian automobile sector is one of the most prominent sectors of the country, accounting for nearly 7.1% of the national GDP. The industry produced a total of 25.31 million vehicles, including commercial, passenger, two, and three vehicles and commercial quadricycle in April-March 2017, as against 24.01 million in April-March 2016. However, India has set itself an ambitious target of having only electric vehicles (EV) by 2030, which is expected to increase the demand for lithium-ion batteries in India, significantly.
Plant capacity: 90 Volt, 180 AH Lithium Ion Battery Pack:100,000 Nos per AnnumPlant & machinery: 1017 Lakh
Working capital: -T.C.I: Cost of Project :4978 Lakh
Return: 34.00%Break even: 52.00%
Add to Inquiry Add to Inquiry Basket

Bioplastic Products Manufacturing Industry, Profitable Business Ideas on Biodegradable Products

Bioplastic Products Manufacturing Industry, Profitable Business Ideas on Biodegradable Products. Manufacture of Eco-Friendly Products for Your Daily Life The non-biodegradable plastic products, which are commonly used in households, cannot be recycled for 400 years. Products like plastic carry bags, if disposed unscientifically, are hard to decompose and are a massive threat to soil cultivation Biodegradable substances include food scraps, cotton, wool, wood, human and animal waste, manufactured products based on natural materials (such as paper, and vegetable-oil based soaps). See also degradable and photodegradable. Biodegradable waste includes any organic matter in waste which can be broken down into carbon dioxide, water, methane or simple organic molecules by micro-organisms and other living things by composting, aerobic digestion, anaerobic digestion or similar processes. In waste management, it also includes some inorganic materials which can be decomposed by bacteria. Such materials include gypsum and its products such as plasterboard and other simple organic sulfates which can decompose to yield hydrogen sulphide in anaerobic land-fill conditions. Biodegradable waste can be found in municipal solid waste (sometimes called biodegradable municipal waste, or (BMW) as green waste, food waste, paper waste and biodegradable plastics. Other biodegradable wastes include human waste, manure, sewage, sewage sludge and slaughterhouse waste. In the absence of oxygen, much of this waste will decay to methane by anaerobic digestion. Biodegradable substances are those that degrades or break down naturally. Materials like plants, animals, their waste, paper, fruits, flowers, vegetables fall under biodegradable substances, on the other hand, rubber, plastic, chemicals, paint plastic falls under the category of the non-biodegradable items. Bio-Degradable Plates from Areca Nuts Tree Leaf, Barks and Bamboo Areca nuts tree leaf plate is made of completely organic material, which is a fallen leaf collected from areca palm trees. Palm Leaf plates are made by Mother Nature from the naturally fallen Areca Palm tree leaves found in India. The leaf or Sheath is collected for the tableware. Areca Leaf plates are commonly known as Areca Plate, Areca Palm Leaf Plates, Palm Leaf Plates, Bio Plate, Natural plates, Disposable Plates, Eco friendly Bio-Degradable Dinner Plates, Kitchenware, Dinnerware. Currently no other alternative product in the world can match the unique properties of areca palm leaf plates present in nature. Areca leaf plates are made from the naturally shed leaf sheaths of Areca Nut Tree. The areca leaves are simply collected, pressure washed, scrubbed, sun dried and then with the application of heat and pressure formed into appropriate shaped plates. Plates once used can be used as a good fertilizer which enhances plants growth, a good source of organic manure. The countries that import areca leaf plates from India are shown in the pie chart below given. Areca Leaf Plate exporters in India supply these plates which are in supreme demand owing to their low cost and solid construction on top of it environmental friendly nature. The products are made from high quality leak proof and defect free palm sheath. The global market for foodservice disposables is anticipated to see a steady growth between 2017 and 2021. By the end of 2021, the global foodservice disposables market is estimated to bring in US$ 27,187 Million revenue. Increasing number of restaurants are using disposable plates, cups, trays, bowls, etc. to serve various food items. Majority of the restaurants have started providing catering services, hence the use of foodservice disposables have also increased. Manufacturers are also providing customized foodservice disposables as per the requirement of restaurants. Moreover, increasing number of customers have started using catering services provided by restaurants, especially during celebrations. Meanwhile, in the recent years, retail stores and hospitality industry have also started using foodservice disposables to provide various food products. A rise in the number of restaurants in developing countries and popularity of takeaway meals is fueling the growth of foodservice disposables in Asia Pacific region. Moreover, continuous urbanization, sedentary lifestyles and on-the-go food culture are expected to further propel the growth of the market in the short and medium terms. Easy availability of raw materials used in the manufacturing of biodegradable food service disposables is another factor which will provide the manufacturers with ease of production, thereby increasing the availability of these products in the market. Biodegradable Diapers and Sanitary Napkins Production Sanitary napkins are completely biodegradable and compostable. They are made from a plant-based material such as banana fibre which is extracted from the stems of banana trees. The pads degrade within 6 months of disposal. Women in rural areas use re-usable cloth as sanitary pads and while that is eco-friendly, it is not so hygienic. While plastic-based menstrual hygiene products are available in abundance, it is advisable to switch to a natural, safer product that does not have any harmful chemicals or synthetics fibers. Menstrual hygiene is a subject matter of deep concern in India where women, especially in rural areas face challenges in acquiring hygienic absorbents and develop health risks. Over the years, there has been a significant rise in the awareness levels regarding the benefits offered by biodegradable sanitary napkins. They are environmentally sustainable which can easily be disposed of in natural soil. Moreover, it reduces the chances of infection and skin irritation and they are cost effective as well. On the other hand, non-compostable napkins use chemicals like dioxins, furans, chlorines and fragrances which causes health issues and cannot be recycled and takes hundreds of years to degrade. Consumers are seeking for environmentally friendly diapering options such as diapers, developing innovative technologies such as nanotechnologies that can minimize the environmental impact of disposable baby diapers, and increasing birth rate in developing countries are the factors influencing the growth of the biodegradable baby diapers market in the near future. The global biodegradable diapers market is expected to grow at a CAGR of 10.3% during 2019-2024. Rising environment concerns represents a key factor driving the demand of diapers. Unlike biodegradable diapers, traditional diapers do not degrade well in a landfill. Moreover, they can take around hundreds of years to decompose. The huge amount of untreated waste added to the landfills every year through plastic diapers can also pollute the ground water. Additionally, disposable diapers also consist of several chemicals that can have a negative impact on health. These include dioxins, sodium polyacrylate, tributyl-tin, volatile organic compounds, dyes, fragrances, etc. Biodegradable Disposable Plastic Cutlery Biodegradable plastics are plastics that can be decomposed by the action of living organisms, usually microbes, into water, carbon dioxide, and biomass. Biodegradable plastics are commonly produced with renewable raw materials, micro-organisms, petrochemicals, or combinations of all three. Plastic cutlery is made from a type of plastic known as polystyrene1. Polystyrene or expanded polystyrene is more commonly referred to as Styrofoam. India is slowly becoming a country where people are turning health conscious. Thankfully, biodegradable cutlery has emerged as a better alternative to plastics across the globe and Indians have been early adopters of biodegradable products. The biodegradable plastic packaging market was valued at USD 3.97 billion in 2018, and is expected to reach a market value of USD 10.3 billion by 2024, registering a CAGR of 17.04% during the forecast period of 2019 - 2024. Increasing awareness regarding harmful effects associated with non-biodegradable plastic wastes is a key factor likely to drive the market. The increasing environmental concerns regarding plastic usage (as plastics contain toxic pollutants that harm plants, animals, and people) are driving the use of biodegradable plastic alternatives. Floating plastic waste that survives thousands of years in water can serve as a transportation device for invasive species that disrupt habitats. This aforementioned factor is contributing to the growth of the market. Biodegradable Plastic Pellets Biodegradable plastics are made from all-natural plant materials. These can include corn oil, orange peels, starch, and plants. Traditional plastic is made with chemical fillers that can be harmful to the environment when released when the plastic is melted down. The biodegradable plastics market is expected to reach USD 6.12 billion by 2023, at a CAGR of 15.1% Increasing consumer preference for the environmentally sustainable plastic products and growing regulations and prohibitions against the use of plastic bags and other plastic items are propelling the global biodegradable plastics market. Even though the factors such as growing consumer preference toward eco-friendly plastic products as well as increasing government emphasis on the use of biodegradable plastics are driving the global biodegradable plastics market, the higher cost of biodegradable plastics and shortcomings of biodegradable plastics are anticipated to dampen the market growth. The growing use of biodegradable plastics in the food and beverages industry, as well as rapid growth of packaging industry, is expected to develop new market expansion opportunities for the global biodegradable plastics market in the forthcoming years. Biodegradable plastic is plastic that decomposes naturally in the environment by the action of microorganisms in the environment that metabolize and break down the structure of biodegradable plastic. Which is relatively less harmful to the environment than the traditional plastics. Non-decomposable plastics are a global environmental problem. Governments around the world are dealing with this problem by banning single-use plastics and promoting biodegradable plastics. Moreover, consumers are willing to pay more for biodegradable plastics owing to their eco-friendly nature. Moreover increasing use of biodegradable plastics in packaging and agriculture sectors is drive the global biodegradable plastics market. Polyester Fiber from Corn/Starch PLA (Polylactic acid) comes from fermented plant starch (mostly from corn), and is often referred to as corn starch plastic. It is becoming popular very quickly, because corn-based plastic is a more environmentally-friendly alternative to traditional plastics, which are petroleum-based. Polyester fibers are manufactured from recycled or virgin PET. These fibers can be colored by the method of pigmentation or dope dyeing. Polyester fibers can be classified as staple fibers and bulk continuous fibers (BCF) depending on their length. These fibers can also be manufactured in various geometries such as square, rectangular, triangular, hexagonal and circular depending upon the area of application. Polyester is the most used and most preferred fibre in the textiles industry due to its better physical properties, lower price, versatility, and recyclability, which offer a completely unique set of benefits unmatched by any other natural or synthetic fibers. Polyester fibers are extremely strong, resistant to most chemicals and shrinking, stretching, abrasion, wrinkle and mildew resistant. Polyester fibers are hydrophobic in nature and dry quickly. Therefore, they can be used to provide insulation in the form of hollow fibers. Polyester fibers withstand wear and tear longer than cotton and retain their shapes in extreme climatic conditions and are thus preferred for manufacturing outdoor clothing. The soluble corn fibre market can be segmented on the basis of its application as food & beverages, nutraceuticals and clinical nutrition, animal nutrition and others. It can also be classified on the basis of end-user usage pattern of soluble corn fibre into breakfast, lunch, dinner and on-the-go eating. One of the major advantages of soluble corn fibre is, it can be used as low-calorie fillings in a range of food items, specially baked goods and confectionery. In addition, there is a growing demand for soluble corn fibers in frozen entrees such as pasta and tortillas in packaged food industry. Regionally, the market can be divided into Asia-Pacific, North America (the U.S., Canada and Mexico), Western Europe, Eastern Europe, Middle East and North Africa, and Rest of the World (Latin America and South Africa). With the rise in disposable income and a shift towards leading a healthy life, the industry has felt an augmented demand for soluble corn fibers. In addition, advancement in food technologies to produce label-friendly products happens to be a major supply side driver of this market. One of the restraints of the market could be the process stability of corn-soluble ingredients as these products are highly application specific. Production of Bio-Plastic Film Using Biodegradable Resin, PLA (Polylactic Acid) PLA Polylactic Acid, is a biodegradable thermoplastic and aliphatic polyester, derived from renewable and organic resources such as corn starch and sugarcane. Our manufacturing facilities can provide simple cut-to-size or complex CNC manufacturing, and crating for multiwall and twin wall sheet. Polylactic acid or polylactide (PLA) is a thermoplastic aliphatic polyester derived from renewable resources. PLA had the second highest consumption volume of any bioplastic of the world, Although Bio plastic is a biodegradable material that come from renewable sources and can be used to reduce the problem of plastic waste that is suffocating the planet and polluting the environment. These are 100% degradable, equally resistant and versatile, already used in agriculture, textile industry, medicine and, over all, in the container and packaging market, and biopolymers are already becoming popular in cities throughout Europe and the United States. With increasing concerns over the use of plastics, sustainable alternatives to plastics are increasingly in demand. Biopolymers in general and bio plastics in particular, present one such sustainable alternative. The global biodegradable plastics market is expected to reach 16.8 billion by 2022 with CAGR 8.4% between 2016-2022. Rising consumer awareness about global warming and government legislation such as banned on plastic bags will increase the demand for biodegradable plastics across the globe. Plastics that decompose to carbon dioxide and water under the actions of microorganisms is known as biodegradable plastics. Biodegradable plastics are produced by fermentation of sugar or canola oil to produce polylactic acid (PLA) or polyhydroxyalkanoates (PHA) which in turn converted into biodegradable plastics. A sustainable alternative to traditional plastics, bio plastics are plastics that are fully or partially bio based, and biodegradable or compostable. In other words, they are plastics that are made from renewable resources such as corn, tapioca, potatoes, sugar and algae and breaks down faster than traditional plastics, which are typically made from petroleum, and other fossil resources such as natural gas. Bio plastics have numerous applications like packaging, bottles, utensils, furniture etc. Bioplastic Carry Bags and Garbage Bags The process of extrusion then transformed these plastic beads into plastic bags. Trash bags are made from low-density polyethylene (LDPE), which is purported to be flexible, soft, airtight and waterproof. At times, to provide strength to the bags, high-density polyethylene (HDPE) is also used. The biodegradable plastic packaging market was valued at USD 3.97 billion in 2018, and is expected to reach a market value of USD 10.3 billion by 2024, registering a CAGR of 17.04%. The stringent regulations by various governments and federal agencies with an objective to reduce plastic waste and promote biodegradable plastics usage in packaging are boosting the demand of this market. The regulations related to green packaging is increasing. Various companies are required to adopt biodegradable packaging to comply with the standards, which in turn, is propelling the growth of this market. High costs (compared to normal plastic) are restraining the growth of the market, as biodegradable plastic is made from plants' starch and its decomposition needs specific conditions, like temperature, bacteria, humidity, etc. The increasing environmental concerns regarding plastic usage (as plastics contain toxic pollutants that harm plants, animals, and people) are driving the use of biodegradable plastic alternatives. Floating plastic waste that survives thousands of years in water can serve as a transportation device for invasive species that disrupt habitats. This aforementioned factor is contributing to the growth of the market. Eco-friendly initiatives by corporates and abundant availability of raw materials for manufacturing bio plastics are prominent factors driving growth in Asia Pacific bio plastics market. Europe and North America are expected to dominate the overall market of biodegradable packaging. North America is expected to be the largest consumer of the biodegradable packaging market. The developed regions are expected to dominate the overall biodegradable packaging market owing to the presence of mature markets that consist of highly environmental conscious consumers. In addition, the presence of high-spending population is also expected to increase the overall demand for biodegradable packaging in the developed regions. The presence of large populations in Asia Pacific is expected to boost the biodegradable packaging market. Tags #Biodegradable_Plates_Production, #Disposable_Leaf_Plates, #Areca_Leaf_Plate_Presentations, #Arecanut_Leaf_Plate_Manufacturing, #Biodegradable_Plates_Production_from_Areca_Nuts_Tree_Leaf, #Areca_leaf_plates_project_report, #Biodegradable_Diapers_and_Sanitary_Napkins_Production, #Project_Report_on_Sanitary_Napkin_Amp_Baby_Diaper, #Project_Report_on_Sanitary_Napkins, #Sanitary_Napkin_Manufacturing_Project, #Biodegradable_Diapers_and_Sanitary_Napkins_Production, #Indian_Sanitary_Napkin_Market, #Eco_friendly_Sanitary_Napkins_in_India, #Project_Report_on_Biodegradable_Cups_Plates_Plant, #How_to_start_a_biodegradable_plastic_manufacturing_company? New Process for Biodegradable Plastics Production, Plastic Industries Project Reports, Book on Production Biodegradable Plastics, Plastic Industries Project Reports, Biodegradable Plastic Pellets Manufacturing Industry, Project Reports & Profiles, Production Of Polyester Fiber From Corn/starch, Polylactic Acid Production, Production of Polyester Fiber from Corn/Starch, Book on Modern Biodegradable Plastics Polymers Bio Starch, Surfaces and Interfaces in Natural Fibre Reinforced, Production Of Bioplastic Film, Book on Production Biodegradable Plastics Bio plastics, Production of Bioplastic Film using Biodegradable, Bio plastics and biodegradable plastics, Polylactic Acid Manufacturing Plant, Book on Production Biodegradable Plastics, Production of Polylactic Acid Feasibility Report, (PDF) Poly(lactic acid) - Mass Production, Bioplastic Carry Bags And Garbage Bags Production, Biodegradable Plastic Bag Manufacturing Unit, Bioplastic Carry Bags and Garbage Bags Production, Pioneering Bioplastic Companies in India, Biodegradable Plastic Bag?, biodegradable plastic bags business plan, Project Report On Biodegradable Carry Bags, Paper Versus Plastic Bags, How to Start Bioplastic Carry Bags and Garbage Bags Processing Industry in India, (Polylactic Acid) Processing Industry in India, Most Profitable (Polylactic Acid)Processing Business Ideas, Production of Bio-plastic Film using Biodegradable Resin, PLA Processing & Polyester Fiber from Corn/Starch Based Profitable Projects, Biodegradable Disposable Plastic Cutlery Processing Projects, Small Scale Biodegradable Plastic Pellets Processing Projects, Starting a Biodegradable Diapers and Sanitary Napkins Production Processing Business, How to Start a Biodegradable Diapers and Sanitary Napkins Production Business, Bio-Degradable Plates from Areca Nuts Tree Leaf, Barks and Bamboo Based Small Scale Industries Projects, new small scale ideas in Bio-Degradable Plates from Areca Nuts Tree Leaf, Barks and Bamboo processing industry,
Plant capacity: -Plant & machinery: -
Working capital: -T.C.I: -
Return: 1.00%Break even: N/A
Add to Inquiry Add to Inquiry Basket

Lithium Ion Battery (Battery Assembly)

Lithium batteries are now powering a wide range of electrical and electronical devices, including laptop computers, mobile phones, power tools, telecommunication systems and new generations of electric cars and vehicles. Lithium metal batteries and lithium ion batteries. Basically, the difference between them is that lithium metal batteries are those that are not rechargeable, thus, primary, and lithium ion batteries are those that can be recharged. As an example, your laptop or cell phone is likely to have a lithium ion battery, whereas your watch may have a lithium metal battery. During charging, lithium ions (yellow circles) flow from the positive electrode (red) to the negative electrode (blue) through the electrolyte (gray). Electrons also flow from the positive electrode to the negative electrode, but take the longer path around the outer circuit. The electrons and ions combine at the negative electrode and deposit lithium there. The India lithium-ion battery market is expected to grow at a robust CAGR of 29.26% during the forecast period, 2018-2023. The Indian automobile sector is one of the most prominent sectors of the country, accounting for nearly 7.1% of the national GDP. The industry produced a total of 25.31 million vehicles, including commercial, passenger, two, and three vehicles and commercial quadricycle in April-March 2017, as against 24.01 million in April-March 2016. The high cost of lithium-ion batteries was considered earlier as one of the principal difficulties for the implementation of India’s ambitious all-electric vehicle target by 2030. The Indian automobile sector is one of the most prominent sectors of the country, accounting for nearly 7.1% of the national GDP.
Plant capacity: 48 Volt, 20 AH Lithium-Ion Battery Pack: 3498 Nos Per DayPlant & machinery: 5053 Lakh
Working capital: -T.C.I: Cost of Project: 7215 Lakh
Return: 29.00%Break even: 45.00%
Add to Inquiry Add to Inquiry Basket

Solar Panel

Solar panel refers either to a photovoltaic module, a solar thermal energy panel, or to a set of solar photovoltaic (PV) modules electrically connected and mounted on a supporting structure. A PV module is a packaged, connected assembly of solar cells. Solar panels can be used as a component of a larger photovoltaic system to generate and supply electricity in commercial and residential applications. Each module is rated by its DC output power under standard test conditions (STC), and typically ranges from 100 to 320 watts. The efficiency of a module determines the area of a module given the same rated output - an 8% efficient 230 watt module will have twice the area of a 16% efficient 230 watt module. There are a few solar panels available that are exceeding 19% efficiency. A single solar module can produce only a limited amount of power most installations contain multiple modules. A photovoltaic system typically includes a panel or an array of solar modules, an inverter, and sometimes a battery and/or solar tracker and interconnection wiring. India solar power products market is projected to grow at a CAGR of more than 11% to surpass $ 7.6 billion by 2024 on the back of increasingly stringent policy and regulatory framework and rising environmental concerns. The Ministry of New and Renewable Energy has set a target of 100 GW of solar power generation capacity by 2022. To achieve the target, government has taken several initiatives in the form of offering subsidies, financial assistance, incentives to manufacturers, power producers and even customers. The government has also partnered with several nodal agencies at the central and state levels for the installation of off-grid SPV systems. Subsidies are made available to the customers to encourage installation of grid connected rooftop photovoltaics. Additionally, rising per capita income and developments in the photovoltaic technologies are further anticipated to positively influence India solar power products market during forecast period. Few Indian major players are as under Alectrona Energy Pvt. Ltd Alpex Solar Pvt. Ltd. Bright Solar Ltd. Central Electronics Ltd. Devsun Solar Pvt. Ltd
Plant capacity: Solar Panel:83.3 KW / dayPlant & machinery: 162 lakhs
Working capital: -T.C.I: Cost of Project : Rs 804 lakhs
Return: 28.00%Break even: 54.00%
Add to Inquiry Add to Inquiry Basket

Active Pharma Ingredients (API) Amoxicillin Trihydrate, Azithromycin & Paracetamol

Active pharmaceutical ingredients are the active substances that are used in the manufacture of a drug and have a pharmacological effect. They provide health benefits and play a vital role in disease diagnosis, prevention, and treatment. Active pharmaceutical ingredients may be synthesized either chemically or through biotechnological methods. Azithromycin is used to treat certain bacterial infections, such as bronchitis; pneumonia; sexually transmitted diseases (STD); and infections of the ears, lungs, sinuses, skin, throat, and reproductive organs. Paracetamol is a commonly used medicine that can help treat pain and reduce a high temperature (fever). It is often recommended as one of the first treatments for pain, as it's safe for most people to take and side effects are rare. India is the seventh largest country in the world and has the second highest population. It has a parliamentary democratic form of government and has abundant natural resources and sufficient oil reserves. Huge investment promises from different countries predict a bright future for India. It has a well-developed administration and an independent judicial system with an ever-growing consumer base. It has a huge pool of hard-working skilled workers in all fields. The government has set up tax and non-tax incentives to establish new industrial entities in specific sectors, which include energy, ports, highways, electronics, and software. The Make in India initiative was launched by the government in 2014 and received an excellent response from the developed nations. The government has also created special areas dedicated to export, called export-processing zones (EPZs) or special economic zones (SEZs), to encourage foreign investment. The global active pharmaceutical ingredient market size is expected to reach a value of USD 286.6 billion by 2027, registering a CAGR of 6.7% over the forecast period. Factors, such as increasing preference for outsourcing APIs and growing prevalence of various target diseases such as cancer and Cardiovascular Diseases (CVDs) are expected to drive the market growth. Patent expirations of blockbuster drugs give rise to generic versions of these molecules, wherein the manufacturers bear the cost. After a patent expires, R&D investments done by the company are no longer beneficial for the company. API production requires a huge capital amount as the process needs extremely systematic protocols. Thus, pharmaceutical companies benefit from outsourcing API production, as it eliminates the need for labor force and installing expensive manufacturing units. Strategic outsourcing allows companies to focus on their core competencies, ultimately resulting in increased productivity. These factors are also projected to drive the active pharmaceutical ingredient market growth. The growth of active pharmaceutical ingredients market is marked by the huge demand for drugs like analgesics, anti-infectives and diabetes, and pain management drugs. But with the rising trend of increasing research and development (R&D) activities, the demand is experiencing a shift towards the advancement of complex APIs that find use in novel formulations, thereby targeting niche therapeutic areas. This facilitates the development of new technologies and ensures a high quality product. Among the problems for pharmaceutical supply chains during this pandemic are the restrictions and impact of COVID-19 on two of the largest global producers of active pharmaceutical ingredients (APIs) and generics: China and India. APIs is a crucial part of the pharma industry’s strategic plan to combat the COVID-19 pandemic. The majority of APIs for generic drug manufacturing across the globe are sourced from India, which also supplies approximately 30 percent of the generic APIs used in the US. However, Indian manufacturers rely heavily on APIs from China for the production of their medicine formulations, procuring around 70 percent from China, the top global producer and exporter of APIs by volume. Role of Government towards API The coronavirus outbreak disrupting supply of active pharmaceutical ingredients (APIs) and medical devices from China to India, the government has come out with four schemes worth Rs 13,760 crore to encourage manufacturing of bulk drugs and medical devices in the country and their exports. On March 21, the Union Cabinet under the chairmanship of Prime Minister Narendra Modi had approved an expenditure of Rs. 9,940 crore and Rs. 3,820 crore for APIs and medical devices, respectively. The Cabinet also approved a scheme on promotion of bulk drug parks for financing common infrastructure facilities in three bulk drug parks with financial implication of Rs. 3,000 crore for next five years. The government will give grants-in-aid to states with a maximum limit of Rs. 1,000 crore per bulk Drug Park. Parks will have common facilities such as solvent recovery plant, distillation plant, power and steam units, common effluent treatment plant etc. The government further approved production linked incentive (PLI) scheme for promotion of domestic manufacturing of critical KSMs/drug intermediates and APIs in the country with financial implications of Rs. 6,940 crore for next eight years. Financial incentive will be given to eligible manufacturers of identified 53 critical bulk drugs on their incremental sales over the base year (2019-20) for a period of 6 years. Out of 53 identified bulk drugs, 26 are fermentation based bulk drugs and 27 are chemical synthesis based bulk drugs. Rate of incentive will be 20 per cent (of incremental sales value) for fermentation based bulk drugs and 10 per cent for chemical synthesis based bulk drugs. The PLI scheme will lead to expected incremental sales of Rs. 46,400 crore and significant additional employment generation over eight years. The drug industry has welcomed the incentives offered by the government to promote API units in India. Besides APIs, the Cabinet also approved the scheme for promotion of medical device parks in the country in partnership with the states. A maximum grant-in-aid of Rs. 100 crore per park will be provided to the states. It will have financial implications of Rs. 400 crore. The PLI scheme for promoting domestic manufacturing of medical devices will have financial implications of Rs. 3,420 crore for next five years. Medical device is a growing sector and its potential for growth is the highest among all sectors in the healthcare market. It is valued at Rs. 50,026 crore for 2018-19 and is expected to reach to Rs. 86,840 crore by 2021-22. India depends on imports up to an extent of 85 per cent of total domestic demand of medical devices. Union Cabinet scheme on Promotion of Bulk Drug Parks • The scheme on Promotion of Bulk Drug Parks for financing Common Infrastructure Facilities in 3 Bulk Drug Parks with financial implication of Rs. 3,000 crore for next five years. • Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical KSMs/Drug Intermediates and APIs in the country with financial implications of Rs6,940 crore for next eight years. Details: Promotion of Bulk Drug Parks • Decision is to develop 3 mega Bulk Drug parks in India in partnership with States. • Government of India will give Grants-in-Aid to States with a maximum limit of Rs. 1000 Crore per Bulk Drug Park. • Parks will have common facilities such as solvent recovery plant, distillation plant, power & steam units, common effluent treatment plant etc. • A sum of Rs. 3,000 crore has been approved for this scheme for next 5 years. Production Linked Incentive Scheme • Financial incentive will be given to eligible manufacturers of identified 53 critical bulk drugs on their incremental sales over the base year (2019-20) for a period of 6 years. • Out of 53 identified bulk drugs, 26 are fermentation based bulk drugs and 27 are chemical synthesis based bulk drugs. • Rate of incentive will be 20 % (of incremental sales value) for fermentation based bulk drugs and 10% for chemical synthesis based bulk drugs. • A sum of Rs. 6,940 crore has been approved for next 8 years. Few Indian major players are as under Alpha Remedies Ltd Ankur Drugs & Pharma Ltd. Cian Healthcare Ltd Farmson Pharmaceutical Gujarat Pvt. Ltd. Glaxosmithkline Pharmaceuticals Ltd. Pan Drugs Ltd Piramal Enterprises Ltd.
Plant capacity: Paracetamol : 1,000.0 Kgs / day Azithromycin : 500.0 Kgs / day Amoxicillin Trihydrate: 500.0 Kgs dayPlant & machinery: 175 lakhs
Working capital: -T.C.I: Cost of Project : Rs 1322 lakhs
Return: 29.00%Break even: 47.00%
Add to Inquiry Add to Inquiry Basket

Manufacturing of Active Pharma Ingredients (API) (Amoxicillin Trihydrate, Azithromycin & Paracetamol).

Production of Active Pharma Ingredients (API) (Amoxicillin Trihydrate, Azithromycin & Paracetamol). Investment Opportunities in Pharmaceutical Industry. An active ingredient (AI) is that the ingredient in an exceedingly pharmaceutical drug that's biologically active. The similar terms active pharmaceutical ingredient (API) and bulk active i.e. bulk medicine are utilized in medicine, and therefore the term active substance could also be used for natural products. Thus, depending on the drug’s administered dosage, the reactions and results differ. Certain drugs are comprised of more than one kind of API. Amoxicillin is an antibiotic used to treat variety of bacterial infections. These include middle ear infection, strep throat, pneumonia, skin infections, and tract infections among others. It’s taken orally, or less usually by injection. Active Pharmaceutical Ingredient (API), is that the term used to check with the biologically active component of a drug product (e.g. tablet, capsule). Drug products are typically composed of many elements. The aforementioned API is that the primary ingredient. Alternative ingredients are commonly known as "excipients" and these substances are always required to be biologically safe, often making up a variable fraction of the drug product. The procedure for optimizing and compositing this mixture of components utilized in the drug is known as "formulation." Paracetamol is a commonly used medicine that can help treat pain and reduce a high temperature (fever). It is often recommended as one of the first treatments for pain, as it's safe for most people to take and side effects are rare. Azithromycin is an antibiotic used for the treatment of variety of bacterial infections. This includes middle ear infections, strep throat, pneumonia, traveler's diarrhea, and bound alternative intestinal infections it also can be used for variety of sexually transmitted infections, as well as chlamydia and gonorrhea infections. At the side of alternative medications, it's going to even be used for malaria. It may be taken by mouth or intravenously with doses once per day. It is on the world Health Organization's List of Essential Medicines, the safest and most effective medicines required in a very health system. It’s one in all the most usually prescribed antibiotics in children. Trim ox is on the market as a generic medication. Related Books: - Pharmaceutical, Drugs, Proteins Technology Handbooks Azithromycin alone and in combination with different medications is currently being studied for the treatment of coronavirus wellness 2019 (COVID-19). Currently, azithromycin has been used with hydroxychloroquine to treat certain patients with COVID-19. However, there are mixed reports of effectiveness once azithromycin was used at the side of alternative medications to treat other viral respiratory infections. Azithromycin also has been used to treat bacterial infections in hospitalized patients with COVID-19. A lot of information is required before any conclusions may be made regarding the possible advantages and risks of using azithromycin either alone or together with hydroxychloroquine in patients with COVID-19. Amoxicillin Trihydrate may be a hydrate that's the Trihydrate type of amoxicillin; a semisynthetic antibiotic, used either alone or together with potassium clavulanate (under the name Augmentin) for treatment of a variety of bacterial infections. It’s a role as an antibacterial drug and an antimicrobial agent. It contains an amoxicillin. Manufacturing Process The manufacturing process of Paracetamol is summarized in the following steps: -charge acetic acid to the reactor. -add p-nitro phenol as a starting material and iron powder as catalyst. -Heat to temp 80-90 ºC. -The reaction is exothermic and temp will rise to 130 ºC. -After slight cooling -Reflux the reaction at 118ºC for 3-4 hours. -Cool to 60 ºC. -Add methanol to the reaction. -Reflux for 1 hour. -distill the methanol and recycle. -Add water to the obtained cake. -And make a solution -Add activated carbon. -Filter -Dry the cake. -Pulverize the dry cake to get the Paracetamol fine powder. Applications:- Communicable Diseases Oncology Diabetes Cardiovascular Diseases Pain Management Respiratory Diseases Other Therapeutic Applications Role of Government towards API The coronavirus outbreak disrupting supply of active pharmaceutical ingredients (APIs) and medical devices from China to India, the government has come out with four schemes worth Rs 13,760 crore to encourage manufacturing of bulk drugs and medical devices in the country and their exports. On March 21, the Union Cabinet under the chairmanship of Prime Minister Narendra Modi had approved an expenditure of Rs. 9,940 crore and Rs. 3,820 crore for APIs and medical devices, respectively. The Cabinet also approved a scheme on promotion of bulk drug parks for financing common infrastructure facilities in three bulk drug parks with financial implication of Rs. 3,000 crore for next five years. The government will give grants-in-aid to states with a maximum limit of Rs. 1,000 crore per bulk Drug Park. Parks will have common facilities such as solvent recovery plant, distillation plant, power and steam units, common effluent treatment plant etc. The government further approved production linked incentive (PLI) scheme for promotion of domestic manufacturing of critical KSMs/drug intermediates and APIs in the country with financial implications of Rs. 6,940 crore for next eight years. Financial incentive will be given to eligible manufacturers of identified 53 critical bulk drugs on their incremental sales over the base year (2019-20) for a period of 6 years. Out of 53 identified bulk drugs, 26 are fermentation based bulk drugs and 27 are chemical synthesis based bulk drugs. Rate of incentive will be 20 per cent (of incremental sales value) for fermentation based bulk drugs and 10 per cent for chemical synthesis based bulk drugs. The PLI scheme will lead to expected incremental sales of Rs. 46,400 crore and significant additional employment generation over eight years. The drug industry has welcomed the incentives offered by the government to promote API units in India. Besides APIs, the Cabinet also approved the scheme for promotion of medical device parks in the country in partnership with the states. A maximum grant-in-aid of Rs. 100 crore per park will be provided to the states. It will have financial implications of Rs. 400 crore. The PLI scheme for promoting domestic manufacturing of medical devices will have financial implications of Rs. 3,420 crore for next five years. Medical device is a growing sector and its potential for growth is the highest among all sectors in the healthcare market. It is valued at Rs. 50,026 crore for 2018-19 and is expected to reach to Rs. 86,840 crore by 2021-22. India depends on imports up to an extent of 85 per cent of total domestic demand of medical devices. Union Cabinet scheme on Promotion of Bulk Drug Parks • The scheme on Promotion of Bulk Drug Parks for financing Common Infrastructure Facilities in 3 Bulk Drug Parks with financial implication of Rs. 3,000 crore for next five years. • Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical KSMs/Drug Intermediates and APIs in the country with financial implications of Rs6,940 crore for next eight years. Details: Promotion of Bulk Drug Parks • Decision is to develop 3 mega Bulk Drug parks in India in partnership with States. • Government of India will give Grants-in-Aid to States with a maximum limit of Rs. 1000 Crore per Bulk Drug Park. • Parks will have common facilities such as solvent recovery plant, distillation plant, power & steam units, common effluent treatment plant etc. • A sum of Rs. 3,000 crore has been approved for this scheme for next 5 years. Production Linked Incentive Scheme • Financial incentive will be given to eligible manufacturers of identified 53 critical bulk drugs on their incremental sales over the base year (2019-20) for a period of 6 years. • Out of 53 identified bulk drugs, 26 are fermentation based bulk drugs and 27 are chemical synthesis based bulk drugs. • Rate of incentive will be 20 % (of incremental sales value) for fermentation based bulk drugs and 10% for chemical synthesis based bulk drugs. • A sum of Rs. 6,940 crore has been approved for next 8 years. Market Outlook Active Pharmaceutical Ingredient Market is valued at USD 172.69 Billion in 2018 and expected to reach USD 263.80 Billion by 2025 with the CAGR of 6.24% over the forecast period. The increasing incidence of chronic diseases, growing importance of generics, and the increasing uptake of biopharmaceuticals are some of the major factors driving the growth of the global APIs market. On the other hand, the unfavorable drug price control policies across various countries and the increasing penetration of counterfeit drugs are expected to restrain the growth of this market in the coming years. Related Projects: - Pharmaceutical, Drugs, Fine Chemicals, Bulk Drug Intermediates Drugs and over-the-counter (OTC) drugs. In 2019, the prescribed drugs segment is expected to account for the most important share of the APIs market. The demand for drugs falling under this class has increased significantly in recent years because of the rising prevalence of target diseases. Additionally, the most important share of the prescription drugs segment also can be attributed to the increased focus of innovator corporations on the development of specialty drugs and affordability of health care. The implementation of significant federal reforms to improve the affordability of healthcare, especially in the, us has expanded the consumption of each traditional and specialty medicine. Also, inflation has played a key role in enhancing revenue from the sales of prescription drugs, significantly specialty drugs. All these factors are collectively responsible for the large share of this phase. Based on the kind of drug, the APIs market can be classified into two segments prescribed. Manufacturer Insights On the basis of type of manufacturer, the API market has been segmented into merchant and captive APIs. Captive API command the most important share in 2019 because of simple availability of raw materials and intensive capitalization of major key players for the development of high-end manufacturing facilities. API is calculable to be the fastest-growing segment over the forecast period. The segment growth is driven by factors similar to high cost of in-house manufacturing of those molecules and rising demand for biopharmaceuticals. Related Videos: - Pharmaceutical, Drugs, Fine Chemicals, Bulk Drug Intermediates, Pharmaceutical Drugs, Pharma Drug Ingredients Intermediates, Pharmaceutical Bulk Drugs Active Pharmaceutical Ingredient (APIs) are portions of any drugs that are biologically active in nature. The APIs have significant use in the manufacturing of effective and safe medicines. Depending on the drug’s administered dosage, the reactions and results take issue according to the requirement and use for specific treatment of diseases. Sure medicine are contained of over one kind of API. medicine are chosen primarily for his or her active ingredients to treat variety of chronic and infectious diseases similar to diabetes, cancer, arthritis, bone & joint infections, pneumonia, otitis, streptococcal pharyngitis, cellulites, and tract infections. However, the standard will vary widely from one whole to a different. Medicine are chosen primarily from active ingredients within the liquid or solid form like tablet or alternative throughout. Global Active Pharmaceutical Ingredient Market Dynamics The key issue for growth of worldwide Active Pharmaceutical Ingredient market is that the rise of demand for the new drug discovery for treatment of various chronic and infectious diseases like HIV, cancer, arthritis, bone & joint infections, hepatitis-B, Aids etc. across the world. According to WHO in 2018, the worldwide cancer burden has up to 18.1 million new cases as well as 9.6 million deaths across the world. Because of such rise within the cases of cancer, the new drugs discovery using the Active Pharmaceutical Ingredient has become essential. Recently in line with the American Chemical Society in 2019, there has been 48 new drugs has been approved by the fad U.S. out of that 11 for new cancer treatments with the innovative molecular pharmaceutical ingredients. However, the Active Pharmaceutical Ingredient market is hampered by would like for prime investment with huge capital demand for research and developments. Moreover rising health cautiousness among the people with technological advancement immense investment for launching of recent drugs and biological products, acquisitions, collaborations, and regional growth can provide huge opportunity for Active Pharmaceutical Ingredient market. For instance in 2019, Raquel has been acquired by Merck & Co. for roughly around USD 2.7 billion in cash, for making cancer drug using Active Pharmaceutical Ingredient with the most recent small-molecule-focused. Expansion of Manufacturing Facilities Creating Lucrative Opportunities for Market Growth Majority of specialty API companies are increasing their manufacturing facilities for specialty active pharmaceutical ingredients (API) to take care of or gain market share. Substantial investments within the growth of approved specialty active pharmaceutical ingredients (API) is one in all the most important factors among key players in the specialty active pharmaceutical ingredients (API) market. For instance, in early 2020, Wuxi STA opened oligonucleotide API manufacturing facility in Changzhou, China to cope up with the increasing demand. In 2018, Cordon Pharma expanded operations with new commercial oligonucleotide active pharmaceutical ingredients (API) manufacturing capabilities at its FDA inspected Colorado facility. The emergence of COVID-19 has brought the world to a standstill. We perceive that this health crisis has brought an unprecedented impact on businesses across industries. However, this too shall pass. Rising support from governments and several companies will help within the fight against this highly contagious disease. There are some industries that are struggling and some are thriving. Overall, almost each sector is anticipated to be impacted by the pandemic. Focus on healthcare to drive the active pharmaceutical ingredients market The spending on healthcare has grown at a rapid pace in recent years and it increased at a CAGR of 6.92% between the years 2003 and 2013. The healthcare spending growth was significantly higher than the population growth rate that grew at a CAGR of 1.22% for the same period. The per capita healthcare spending rose from just under US$ 600 in 2003 to above US$ 1000 in 2013, at an average CAGR of 5.62%. The focus on healthcare spending was observed to be a global phenomenon and this directly benefited the active pharmaceutical ingredients market. Related Videos: - Active Pharma Ingredients (API) - Global Market Estimated to Reach US$ 21.9 billion by 2023 Investment Opportunities in API Bulk Drugs & Intermediates Manufacturing Unit Production of Paracetamol (Acetaminophen), bulk pharmaceutical active ingredient Investment Opportunities in APIs KSMs Drug Intermediates Bulk Drug Industries Manufacturing Business Ideas in Pharmaceutical Industry Key Players Pfizer, Inc. (US), Novartis AG (Switzerland), Sanofi (France), Boehringer Ingelheim (Germany), Bristol-Myers Squibb (US), Teva Pharmaceutical Industries Ltd. (Israel), Eli Lilly and Company (US), GlaxoSmithKline plc (UK), Merck & Co., Inc. (US), AbbVie Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), and AstraZeneca plc (UK). Sun Pharmaceutical Industries Ltd. Tags:- #Activepharmaingredients #pharmaingredients #IndianPharma #medicineingredients #paracetamolingredients #amoxicillinTrihydrate #Azithromycin #COVID19 #Paracetamol #coronavirus #CoronavirusBusiness #COVID2019 #CaronaBUSINESS #lockdownbusiness #businessinlockdown #coronavirusbusiness #Entrepreneurs #covid19business #DetailedProjectReport #businessconsultant #BusinessPlan #feasibilityReport #NPCS #industrialproject #entrepreneurindia #startupbusiness #startupbusinessideas #businessestostart #startupideas #startupbusinesswithnomoney #businessstartupindia #API
Plant capacity: -Plant & machinery: -
Working capital: -T.C.I: -
Return: 1.00%Break even: N/A
Add to Inquiry Add to Inquiry Basket

Active Pharma Ingredients (API) Amoxicillin Trihydrate, Azithromycin & Paracetamol

Active pharmaceutical ingredients are the active substances that are used in the manufacture of a drug and have a pharmacological effect. They provide health benefits and play a vital role in disease diagnosis, prevention, and treatment. Active pharmaceutical ingredients may be synthesized either chemically or through biotechnological methods. The Active Pharmaceutical Ingredient (API) is the part of any drug that produces the intended effects. Some drugs, such as combination therapies, have multiple active ingredients to treat different symptoms or act in different ways. Active Pharmaceutical Ingredient (API), is the term used to refer to the biologically active component of a drug product (e.g. tablet, capsule). Drug products are usually composed of several components. The aforementioned API is the primary ingredient. Other ingredients are commonly known as "excipients" and these substances are always required to be biologically safe, often making up a variable fraction of the drug product. The procedure for optimizing and compositing this mixture of components used in the drug is known as "formulation." India is the seventh largest country in the world and has the second highest population. It has a parliamentary democratic form of government and has abundant natural resources and sufficient oil reserves. The country has a huge skilled, English-speaking, and inexpensive labor force. Its young population and current economic policies have made it one of the largest recipients of FDI in the world. The global active pharmaceutical ingredient market size is expected to reach a value of USD 286.6 billion by 2027, registering a CAGR of 6.7% over the forecast period. Factors, such as increasing preference for outsourcing APIs and growing prevalence of various target diseases such as cancer and Cardiovascular Diseases (CVDs) are expected to drive the market growth. Majority of specialty API companies are increasing their manufacturing facilities for specialty active pharmaceutical ingredients (API) to take care of or gain market share. Substantial investments within the growth of approved specialty active pharmaceutical ingredients (API) is one in all the most important factors among key players in the specialty active pharmaceutical ingredients (API) market. For instance, in early 2020, Wuxi STA opened oligonucleotide API manufacturing facility in Changzhou, China to cope up with the increasing demand. In 2018, Cordon Pharma expanded operations with new commercial oligonucleotide active pharmaceutical ingredients (API) manufacturing capabilities at its FDA inspected Colorado facility. The emergence of COVID-19 has brought the world to a standstill. We perceive that this health crisis has brought an unprecedented impact on businesses across industries. However, this too shall pass. Rising support from governments and several companies will help within the fight against this highly contagious disease. There are some industries that are struggling and some are thriving. Overall, almost each sector is anticipated to be impacted by the pandemic. Role of Government towards API The coronavirus outbreak disrupting supply of active pharmaceutical ingredients (APIs) and medical devices from China to India, the government has come out with four schemes worth Rs 13,760 crore to encourage manufacturing of bulk drugs and medical devices in the country and their exports. On March 21, the Union Cabinet under the chairmanship of Prime Minister Narendra Modi had approved an expenditure of Rs. 9,940 crore and Rs. 3,820 crore for APIs and medical devices, respectively. The Cabinet also approved a scheme on promotion of bulk drug parks for financing common infrastructure facilities in three bulk drug parks with financial implication of Rs. 3,000 crore for next five years. The government will give grants-in-aid to states with a maximum limit of Rs. 1,000 crore per bulk Drug Park. Parks will have common facilities such as solvent recovery plant, distillation plant, power and steam units, common effluent treatment plant etc. The government further approved production linked incentive (PLI) scheme for promotion of domestic manufacturing of critical KSMs/drug intermediates and APIs in the country with financial implications of Rs. 6,940 crore for next eight years. Financial incentive will be given to eligible manufacturers of identified 53 critical bulk drugs on their incremental sales over the base year (2019-20) for a period of 6 years. Out of 53 identified bulk drugs, 26 are fermentation based bulk drugs and 27 are chemical synthesis based bulk drugs. Rate of incentive will be 20 per cent (of incremental sales value) for fermentation based bulk drugs and 10 per cent for chemical synthesis based bulk drugs. The PLI scheme will lead to expected incremental sales of Rs. 46,400 crore and significant additional employment generation over eight years. The drug industry has welcomed the incentives offered by the government to promote API units in India. Besides APIs, the Cabinet also approved the scheme for promotion of medical device parks in the country in partnership with the states. A maximum grant-in-aid of Rs. 100 crore per park will be provided to the states. It will have financial implications of Rs. 400 crore. The PLI scheme for promoting domestic manufacturing of medical devices will have financial implications of Rs. 3,420 crore for next five years. Medical device is a growing sector and its potential for growth is the highest among all sectors in the healthcare market. It is valued at Rs. 50,026 crore for 2018-19 and is expected to reach to Rs. 86,840 crore by 2021-22. India depends on imports up to an extent of 85 per cent of total domestic demand of medical devices. Union Cabinet scheme on Promotion of Bulk Drug Parks • The scheme on Promotion of Bulk Drug Parks for financing Common Infrastructure Facilities in 3 Bulk Drug Parks with financial implication of Rs. 3,000 crore for next five years. • Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical KSMs/Drug Intermediates and APIs in the country with financial implications of Rs6,940 crore for next eight years. Details: Promotion of Bulk Drug Parks • Decision is to develop 3 mega Bulk Drug parks in India in partnership with States. • Government of India will give Grants-in-Aid to States with a maximum limit of Rs. 1000 Crore per Bulk Drug Park. • Parks will have common facilities such as solvent recovery plant, distillation plant, power & steam units, common effluent treatment plant etc. • A sum of Rs. 3,000 crore has been approved for this scheme for next 5 years. Production Linked Incentive Scheme • Financial incentive will be given to eligible manufacturers of identified 53 critical bulk drugs on their incremental sales over the base year (2019-20) for a period of 6 years. • Out of 53 identified bulk drugs, 26 are fermentation based bulk drugs and 27 are chemical synthesis based bulk drugs. • Rate of incentive will be 20 % (of incremental sales value) for fermentation based bulk drugs and 10% for chemical synthesis based bulk drugs. • A sum of Rs. 6,940 crore has been approved for next 8 years. Few Indian major players are as under Alpha Remedies Ltd Ankur Drugs & Pharma Ltd. Aurobindo Pharma Ltd. Dr. Reddy'S Laboratories Ltd. Glaxosmithkline Pharmaceuticals Ltd. Farmson Pharmaceutical Gujarat Pvt. Ltd.
Plant capacity: Paracetamol:1,000 Kgs / day Azithromycin:500 Kgs / day Amoxicillin Trihydrate:500 Kgs / dayPlant & machinery: Rs 175 lakhs
Working capital: -T.C.I: Cost of Project : Rs 1322 lakhs
Return: 29.00%Break even: 47.00%
Add to Inquiry Add to Inquiry Basket

Active Pharma Ingredients (API) (Cephalexin, Ampicillin Trihydrate, Ibuprofen and Paracetamol)

The Active Pharmaceutical Ingredient (API) is the part of any drug that produces the intended effects. Some drugs, such as combination therapies, have multiple active ingredients to treat different symptoms or act in different ways. Production of APIs has traditionally been done by the pharmaceutical companies themselves in their home countries. But in recent years many corporations have opted to send manufacturing overseas to cut costs. This has caused significant changes to how these drugs are regulated, with more rigorous guidelines and inspections put into place. Cefalexin, is an antibiotic that can treat a number of bacterial infections. It kills gram-positive and some gram-negative bacteria by disrupting the growth of the bacterial cell wall. Cefalexin is a beta-lactam antibiotic within the class of first-generation cephalosporins. It works similarly to other agents within this class, including intravenous cefazolin, but can be taken by mouth. Cefalexin can be used in those who have mild or moderate allergies to penicillin. However, it is not recommended in those with severe penicillin allergies. Ampicillin is an antibiotic used to prevent and treat a number of bacterial infections, such as respiratory tract infections, urinary tract infections, meningitis, salmonellosis, and endocarditis. It may also be used to prevent group B streptococcal infection in newborns. It is used by mouth, by injection into a muscle, or intravenously. Like all antibiotics, it is not useful for the treatment of viral infections. Ampicillin is used to treat infections by many Gram-positive and Gram-negative bacteria. It was the first "broad spectrum" penicillin with activity against Gram-positive bacteria, including Streptococcus pneumoniae, Streptococcus pyogenes, some isolates of Staphylococcus aureus (but not penicillin-resistant or methicillin-resistant strains), Trueperella, and some Enterococcus. Paracetamol (acetaminophen) is a pain reliever and a fever reducer. The exact mechanism of action of is not known. Paracetamol is used to treat many conditions such as headache, muscle aches, arthritis, backache, toothaches, colds, and fevers. It relieves pain in mild arthritis but has no effect on the underlying inflammation and swelling of the joint. Paracetamol is generally safe at recommended doses. The recommended maximum daily dose for an adult is three to four grams. Higher doses may lead to toxicity, including liver failure. Serious skin rashes may rarely occur. It appears to be safe during pregnancy and when breastfeeding. In those with liver disease, it may still be used, but in lower doses. It is classified as a mild analgesic. It does not have significant anti-inflammatory activity. How it works is not entirely clear. Ibuprofen is a medication in the nonsteroidal anti-inflammatory drug (NSAID) class that is used for treating pain, fever, and inflammation. This includes painful menstrual periods, migraines, and rheumatoid arthritis. It may also be used to close a patent ductus arteriosus in a premature baby. It can be used by mouth or intravenously. It typically begins working within an hour India's reliance on pharma ingredient imports has risen over the past few decades due to the higher cost of domestic production, with the price gap reaching as much as 20%-30%, particularly for energy-intensive fermentation-based ingredients used in anti-infectives. Import dependence is more than 90% for some life-saving drugs, including penicillin and ciprofloxacin. India is the seventh largest country in the world and has the second highest population. It has a parliamentary democratic form of government and has abundant natural resources and sufficient oil reserves. The country has a huge skilled, English-speaking, and inexpensive labor force. Its young population and current economic policies have made it one of the largest recipients of FDI in the world. Asia Pacific is expected to be the fastest-growing market over the forecast period. Owing to the availability of affordable labor, major companies in the market are setting up API manufacturing plants in developing countries such as China and India. The global demand of APIs include ageing population, rising expenditures on healthcare, increasing prevalence of lifestyle diseases, etc. Looking forward, the market value is projected to reach US$ 258.8 Billion by 2025, exhibiting a CAGR of 5.6% during 2020-2025. The API market is competitive in nature and is becoming increasingly competitive. Consequently, manufacturers are required to enhance products in order to gain advantage over previously marketed products. The emergence of COVID-19 has brought the world to a standstill. We perceive that this health crisis has brought an unprecedented impact on businesses across industries. However, this too shall pass. Rising support from governments and several companies will help within the fight against this highly contagious disease. There are some industries that are struggling and some are thriving. Overall, almost each sector is anticipated to be impacted by the pandemic. The government also notified a scheme to promote bulk drug parks. For selected parks, financial assistance to the tune of 70 per cent of the project cost of common infrastructure facilities will be provided. In the case of Northeast states and hilly states (Himachal Pradesh, Uttarakhand, Union Territory of Jammu & Kashmir, and Union Territory of Ladakh), financial assistance will be 90 per cent of the project cost. The maximum assistance under the scheme for one bulk Drug Park will be limited to Rs 1,000 crore. The total financial outlay of the scheme is Rs 3,000 crore. Role of Government towards API The coronavirus outbreak disrupting supply of active pharmaceutical ingredients (APIs) and medical devices from China to India, the government has come out with four schemes worth Rs 13,760 crore to encourage manufacturing of bulk drugs and medical devices in the country and their exports. On March 21, the Union Cabinet under the chairmanship of Prime Minister Narendra Modi had approved an expenditure of Rs. 9,940 crore and Rs. 3,820 crore for APIs and medical devices, respectively. The Cabinet also approved a scheme on promotion of bulk drug parks for financing common infrastructure facilities in three bulk drug parks with financial implication of Rs. 3,000 crore for next five years. The government will give grants-in-aid to states with a maximum limit of Rs. 1,000 crore per bulk Drug Park. Parks will have common facilities such as solvent recovery plant, distillation plant, power and steam units, common effluent treatment plant etc. The government further approved production linked incentive (PLI) scheme for promotion of domestic manufacturing of critical KSMs/drug intermediates and APIs in the country with financial implications of Rs. 6,940 crore for next eight years. Financial incentive will be given to eligible manufacturers of identified 53 critical bulk drugs on their incremental sales over the base year (2019-20) for a period of 6 years. Out of 53 identified bulk drugs, 26 are fermentation based bulk drugs and 27 are chemical synthesis based bulk drugs. Rate of incentive will be 20 per cent (of incremental sales value) for fermentation based bulk drugs and 10 per cent for chemical synthesis based bulk drugs. The PLI scheme will lead to expected incremental sales of Rs. 46,400 crore and significant additional employment generation over eight years. The drug industry has welcomed the incentives offered by the government to promote API units in India. Besides APIs, the Cabinet also approved the scheme for promotion of medical device parks in the country in partnership with the states. A maximum grant-in-aid of Rs. 100 crore per park will be provided to the states. It will have financial implications of Rs. 400 crore. The PLI scheme for promoting domestic manufacturing of medical devices will have financial implications of Rs. 3,420 crore for next five years. Medical device is a growing sector and its potential for growth is the highest among all sectors in the healthcare market. It is valued at Rs. 50,026 crore for 2018-19 and is expected to reach to Rs. 86,840 crore by 2021-22. India depends on imports up to an extent of 85 per cent of total domestic demand of medical devices. Union Cabinet scheme on Promotion of Bulk Drug Parks • The scheme on Promotion of Bulk Drug Parks for financing Common Infrastructure Facilities in 3 Bulk Drug Parks with financial implication of Rs. 3,000 crore for next five years. • Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical KSMs/Drug Intermediates and APIs in the country with financial implications of Rs6,940 crore for next eight years. Details: Promotion of Bulk Drug Parks • Decision is to develop 3 mega Bulk Drug parks in India in partnership with States. • Government of India will give Grants-in-Aid to States with a maximum limit of Rs. 1000 Crore per Bulk Drug Park. • Parks will have common facilities such as solvent recovery plant, distillation plant, power & steam units, common effluent treatment plant etc. • A sum of Rs. 3,000 crore has been approved for this scheme for next 5 years. Production Linked Incentive Scheme • Financial incentive will be given to eligible manufacturers of identified 53 critical bulk drugs on their incremental sales over the base year (2019-20) for a period of 6 years. • Out of 53 identified bulk drugs, 26 are fermentation based bulk drugs and 27 are chemical synthesis based bulk drugs. • Rate of incentive will be 20 % (of incremental sales value) for fermentation based bulk drugs and 10% for chemical synthesis based bulk drugs. • A sum of Rs. 6,940 crore has been approved for next 8 years. Few Indian major players are as under Alpha Remedies Ltd. Ankur Drugs & Pharma Ltd. Aurobindo Pharma Ltd. Cian Healthcare Ltd Cipla Ltd. Dr. Reddy'S Laboratories Ltd. Farmson Pharmaceutical Gujarat Pvt. Ltd. Glaxosmithkline Pharmaceuticals Ltd. Indoco Remedies Ltd. Pan Drugs Ltd. Piramal Enterprises Ltd.
Plant capacity: Paracetamol: 500 Kgs / day Cephalexin: 500 Kgs / day Ampicillin Trihydrate: 500 Kgs / day Ibuprofen: 500 Kgs / dayPlant & machinery: Rs 347 lakhs
Working capital: -T.C.I: Cost of Project: Rs 1656 lakhs
Return: 36.00%Break even: 52.00%
Add to Inquiry Add to Inquiry Basket

API Production. Manufacturing of Active Pharma Ingredients (API), Cephalexin, Ampicillin Trihydrate, Ibuprofen and Paracetamol.

API Production. Manufacturing of Active Pharma Ingredients (API), Cephalexin, Ampicillin Trihydrate, Ibuprofen and Paracetamol. API (Active Pharmaceutical Ingredient) means the active ingredient which is contained in medicine. For example, an active ingredient to relieve pain is included in a painkiller. This is called API. A small amount of the active ingredient has an effect, so only a tiny part of the active ingredient is contained in medicine. Related Projects:- Active Pharma Ingredients (api) The API form that is used in a formulation is often the most thermodynamically stable crystalline form. As such, the phenomenon of hydrogen bonding in combination with there being many functional groups on the API usually results in the available crystalline form being a hydrate. Related Books: - Pharmaceutical, Drugs, Proteins Technology Handbooks Ampicillin is used to treat infections by many Gram-positive and Gram-negative bacteria. It was the first "broad spectrum" penicillin with activity against Gram-positive bacteria, including Streptococcus pneumonia, Streptococcus pyogenic, some isolates of Staphylococcus aureus (but not penicillin-resistant or methicillin-resistant strains), Trueperella, and some Enterococcus. Paracetamol is used for the relief of mild to moderate pain. The use of the intravenous form for short-term pain in people in the emergency department is supported by limited evidence. In adults it appears to be useful for migraines, tension headaches, perineal pain after childbirth, and kidney stone pain. Related Projects: - Pharmaceutical, Drugs, Fine Chemicals, Bulk Drug Intermediates Ibuprofen is a medication in the nonsteroidal anti-inflammatory drug class that is used for treating pain, fever, and inflammation. This includes painful menstrual periods, migraines, and rheumatoid arthritis. It may also be used to close a patent ductus arteriosus in a premature baby. Market Outlook The production-linked incentive scheme - which accounts for INR0.9 billion of planned outlay - offers an incentive of up to 20% of sales for fermentation based products and up to 10% for chemical synthesis-based products for the next eight to nine years. This should help to bridge the price gap and make domestic production more competitive. The government has also allocated USD0.4 billion under the capex assistance scheme to fund up to 90% of the investment need to build common infrastructure facilities in three bulk drug parks. We believe this will aid the investment decisions of Indian pharma companies, particularly in the current environment where the focus in on conserving cash. Related Videos: - Pharmaceutical, Drugs, Fine Chemicals, Bulk Drug Intermediates, Pharmaceutical Drugs, Pharma Drug Ingredients Intermediates, Pharmaceutical Bulk Drugs The increasing incidence of chronic diseases, growing importance of generics, and the increasing uptake of biopharmaceuticals are some of the major factors driving the growth of the global APIs market. On the other hand, the unfavorable drug price control policies across various countries and the increasing penetration of counterfeit drugs are expected to restrain the growth of this market in the coming years. Active pharmaceutical ingredients are an active ingredient of any drug or tablet, which possesses medicinal properties. Some drugs with combined therapy have many active ingredients to treat different disorders. Related Videos: - Active Pharma Ingredients (API) - Global Market Estimated to Reach US$ 21.9 billion by 2023 Higher Growth in the APAC Active Pharmaceutical Ingredients Market Healthcare spending has witnessed continued growth for some time now. Even though the proportion of healthcare spending in the APAC region is comparatively low, the growth rate in this strategic region has outpaced that of mature markets in North America and Europe. Rising healthcare spending has led to quality healthcare becoming accessible along with a higher demand for pharmaceutical products across APAC. The pharmaceuticals consumed here are mostly produced in onshore manufacturing units. Furthermore, contract manufacturing organizations are key outsourcing allies for pharmaceutical companies that supply their wares to North America and Europe. Books:- BOOKS & DATABASES Huge investment promises from different countries predict a bright future for India. It has a well-developed administration and an independent judicial system with an ever-growing consumer base. It has a huge pool of hard-working skilled workers in all fields. The government has set up tax and non-tax incentives to establish new industrial entities in specific sectors, which include energy, ports, highways, electronics, and software. Related Videos:- Investment Opportunities in API Bulk Drugs & Intermediates Manufacturing Unit The global active pharmaceutical ingredients market has been broadly segmented based on manufacturer, APIs, drug, therapeutic, and region. In terms of manufacturer, the global market has been classified into in-house API manufacturing and API contract manufacturing. The increasing incidence of chronic diseases, growing importance of generics, and the increasing uptake of biopharmaceuticals are some of the major factors driving the growth of the global APIs market. On the other hand, the unfavorable drug price control policies across various countries and the increasing penetration of counterfeit drugs are expected to restrain the growth of this market in the coming years. Related Videos:- Manufacturing Business Ideas in Pharmaceutical Industry Role of Government towards API The coronavirus outbreak disrupting supply of active pharmaceutical ingredients (APIs) and medical devices from China to India, the government has come out with four schemes worth Rs 13,760 crore to encourage manufacturing of bulk drugs and medical devices in the country and their exports. On March 21, the Union Cabinet under the chairmanship of Prime Minister Narendra Modi had approved an expenditure of Rs. 9,940 crore and Rs. 3,820 crore for APIs and medical devices, respectively. The Cabinet also approved a scheme on promotion of bulk drug parks for financing common infrastructure facilities in three bulk drug parks with financial implication of Rs. 3,000 crore for next five years. The government will give grants-in-aid to states with a maximum limit of Rs. 1,000 crore per bulk Drug Park. Parks will have common facilities such as solvent recovery plant, distillation plant, power and steam units, common effluent treatment plant etc. Related Projects:- Startup Opportunities in Active Pharma Ingredients The government further approved production linked incentive (PLI) scheme for promotion of domestic manufacturing of critical KSMs/drug intermediates and APIs in the country with financial implications of Rs. 6,940 crore for next eight years. Financial incentive will be given to eligible manufacturers of identified 53 critical bulk drugs on their incremental sales over the base year (2019-20) for a period of 6 years. Out of 53 identified bulk drugs, 26 are fermentation based bulk drugs and 27 are chemical synthesis based bulk drugs. Rate of incentive will be 20 per cent (of incremental sales value) for fermentation based bulk drugs and 10 per cent for chemical synthesis based bulk drugs. The PLI scheme will lead to expected incremental sales of Rs. 46,400 crore and significant additional employment generation over eight years. Market Research Reports:- India Active Pharmaceutical Ingredient (API) The drug industry has welcomed the incentives offered by the government to promote API units in India. Besides APIs, the Cabinet also approved the scheme for promotion of medical device parks in the country in partnership with the states. A maximum grant-in-aid of Rs. 100 crore per park will be provided to the states. It will have financial implications of Rs. 400 crore. The PLI scheme for promoting domestic manufacturing of medical devices will have financial implications of Rs. 3,420 crore for next five years. Market Research:- Market Research Reports Medical device is a growing sector and its potential for growth is the highest among all sectors in the healthcare market. It is valued at Rs. 50,026 crore for 2018-19 and is expected to reach to Rs. 86,840 crore by 2021-22. India depends on imports up to an extent of 85 per cent of total domestic demand of medical devices. Related Projects: - Investment Opportunities in API Bulk Drugs & Intermediates Manufacturing Unit Union Cabinet scheme on Promotion of Bulk Drug Parks • The scheme on Promotion of Bulk Drug Parks for financing Common Infrastructure Facilities in 3 Bulk Drug Parks with financial implication of Rs. 3,000 crore for next five years. • Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical KSMs/Drug Intermediates and APIs in the country with financial implications of Rs6,940 crore for next eight years. Related Projects:- Active Pharma Ingredients (api) (cephalexin, Ampicillin Trihydrate, Ibuprofen And Paracetamol) Details: Promotion of Bulk Drug Parks • Decision is to develop 3 mega Bulk Drug parks in India in partnership with States. • Government of India will give Grants-in-Aid to States with a maximum limit of Rs. 1000 Crore per Bulk Drug Park. • Parks will have common facilities such as solvent recovery plant, distillation plant, power & steam units, common effluent treatment plant etc. • A sum of Rs. 3,000 crore has been approved for this scheme for next 5 years. Related Projects: - Active Pharma Ingredients (API) Production Linked Incentive Scheme • Financial incentive will be given to eligible manufacturers of identified 53 critical bulk drugs on their incremental sales over the base year (2019-20) for a period of 6 years. • Out of 53 identified bulk drugs, 26 are fermentation based bulk drugs and 27 are chemical synthesis based bulk drugs. • Rate of incentive will be 20 % (of incremental sales value) for fermentation based bulk drugs and 10% for chemical synthesis based bulk drugs. • A sum of Rs. 6,940 crore has been approved for next 8 years. Projects: - Project Reports & Profiles For More Details, Click Here: - Key players Alpha Remedies Ltd. Ankur Drugs & Pharma Ltd. Aurobindo Pharma Ltd. Cian Healthcare Ltd Cipla Ltd. Dr. Reddy'S Laboratories Ltd. Farmson Pharmaceutical Gujarat Pvt. Ltd. Glaxosmithkline Pharmaceuticals Ltd. Indoco Remedies Ltd. Pan Drugs Ltd. Piramal Enterprises Ltd. Sanofi India Ltd. Sri Krishna Pharmaceuticals Ltd. Teva Pharmaceutical & Chemical Inds. India Pvt. Ltd. Triton Laboratories Ltd. For More Details, Click Here: - https://bit.ly/32McBPb Tags:- #Activepharmaingredients #pharmaingredients #IndianPharma #medicineingredients #paracetamolingredients #amoxicillinTrihydrate #Azithromycin #COVID19 #Paracetamol #coronavirus #CoronavirusBusiness #COVID2019 #CaronaBUSINESS #lockdownbusiness #businessinlockdown #coronavirusbusiness #Entrepreneurs #covid19business #DetailedProjectReport #businessconsultant #BusinessPlan #feasibilityReport #NPCS #industrialproject #entrepreneurindia #startupbusiness #startupbusinessideas #businessestostart #startupideas #startupbusinesswithnomoney #businessstartupindia #API
Plant capacity: -Plant & machinery: -
Working capital: -T.C.I: -
Return: 1.00%Break even: N/A
Add to Inquiry Add to Inquiry Basket

Disposable Surgical Mask Production. Investment and Business Opportunities in Medical Disposable Industry.

Disposable Surgical Mask Production. Investment and Business Opportunities in Medical Disposable Industry. Face masks are one tool utilized for preventing the spread of disease. They’ll even be called dental, isolation, laser, medical, procedure, or surgical masks. Face masks are loose-fitting masks that cover the nose and mouth, and have ear loops or ties or bands at the rear of the top. There are many various brands and that they are available different colors. It’s important to use a mask approved by the FDA. Related Projects:- Disposable Surgical Masks A surgical mask, also referred to as a face mask, is meant to be worn by health professionals during healthcare procedures. It’s designed to stop infections in patients and treating personnel by catching bacteria shed in liquid droplets and aerosols from the wearer's mouth and nose. They’re not designed to guard the wearer from breathing in airborne bacteria or viruses whose particles are smaller. With reference to some infections like influenza they seem as effective as respirators, such as N95 or FFP masks though the latter provide better protection in laboratory experiments because of their material, shape and tight seal. Related Books:- Disposable Products (Medical, Surgical, Thermocol, Plastic, Paper, Domestic And General Products) - Use And Throw Items, Single Use Items, Disposable Take-Away Packaging, Disposable Items Manufacturing Uses Disposable face masks are medical supplies that are worn to cover the mouth and nose and prevent people from inhaling poisonous airborne substances or other impure substances. Alternatively, it also is a shield against ill people that may unintentionally spread illnesses via the contaminants which may begin of their mouth. Generally, in medical health care centre, disposable face masks are wont to prevent the spread of infections from patients who are sick. The masks are quite effective when the patient comes in touch with people. However, facemasks also are worn by the hospital staff and employees working in medical healthcare institutions because they frequently affect different sorts of patients having varied varieties of diseases. Research Report: - Market Research Report Disposable face masks are known by different names. A number of these terms are surgery masks, medical procedure masks, and laser and isolation masks. Face masks are available in different shapes and sizes alongside varied densities of thickness. The thickness of the mask significantly affects the breathing capabilities of the person wearing it. If the thickness of the mask is high, then it'll make the breathing difficult. Which is why, at times, people with affected by asthma and emphysema may need to consult a doctor before wearing face masks. Related Videos: - Manufacturing of Medical Disposable Face Masks. How are Surgical Masks Made? Surgical face masks are made with non-woven fabric, which has better bacteria filtration and air permeability while remaining less slippery than woven cloth. The material most commonly used to make them is polypropylene, either 20 or 25 grams per square meter (gsm) in density. Masks can also be made of polystyrene, polycarbonate, polyethylene, or polyester. Project Identification 20 gsm mask material is made in a spun bond process, which involves extruding the melted plastic onto a conveyor. The material is extruded in a web, in which strands bond with each other as they cool. 25 gsm fabric is made through melt blown technology, which is a similar process where plastic is extruded through a die with hundreds of small nozzles and blown by hot air to become tiny fibers, again cooling and binding on a conveyor. These fibers are less than a micron in diameter. Related Projects:- Surgical, Medical Plastics, Medical Disposables, Disposable Medical Products used in Hospitals Surgical masks are made up of a multi-layered structure, generally by covering a layer of textile with non-woven bonded fabric on both sides. Non-woven, which are cheaper to make and cleaner thanks to their disposable nature, are made with three or four layers. These disposable masks are often made with two filter layers effective at filtering out particles such as bacteria above 1 micron. The filtration level of a mask, however, depends on the fiber, the way it’s manufactured, the web’s structure, and the fiber’s cross-sectional shape. Masks are made on a machine line that assembles the nonwovens from bobbins, ultrasonically welds the layers together, and stamps the masks with nose strips, ear loops, and other pieces. Completed masks are then sterilized before being sent out of the factory. Related Books: - Handbook on Medical and Surgical Disposable Products Market Outlook Indian market Surgical masks are disposable devices that cover the mouth and nose during medical procedures. They prevent the spread of infection between diseased and healthy population. Surgical masks are typically used in a health facility (hospitals, emergency departments, out-patient facilities, residential care facilities, emergency medical services) and home health care delivery. The India surgical mask market was valued at $71.73 million in 2019, and is expected to reach $157.13 million by 2027, registering a CAGR of 10.3% from 2020 to 2027. Related Video: - Production of Disposable Surgical and Medical Face Mask However, surgical disposables like masks, contain absorbent chemicals and are discarded after use. Most of those masks are made from superabsorbent polymers like polyacrylate, which are non-biodegradable. These products contain quite 90% plastic with superabsorbent polymers and non-woven plastic components. Thus, the disposal issue of those masks has become an environmental hazard, which impedes the growth of the India surgical masks market. Similarly, increase in usage of less invasive surgeries is anticipated to decrease the utilization of surgical masks within the upcoming years. Minimally invasive surgeries are estimated to scale back the usage of surgical apparels like surgical masks, caps, and others in hospitals, during operative procedures. Additionally, the utilization of efficient robotics in surgical procedures is further anticipated to scale back the demand for protective apparels required by surgeons during medical procedures. Conversely, technological integration within the process of surgical masks making is predicted to make beneficial opportunities within the future. Advancements in production of reusable nonwoven products like antimicrobial fibers and improved comfort are expected to fuel the expansion of the India surgical masks market. Related Projects:- Disposable Products and Projects from Paper, Plastic, Thermocol, Banana Leaves (Use and Throw Items, Throwing Item, Single Use Items, Disposable Take-Away Packaging, Disposable Food Packaging, Disposable Items Manufacturing) Conversely, increase in concerns regarding the disposal of surgical masks and rise in popularity of lesser invasive surgeries are foreseen to impede the market growth in coming years. On the contrary, innovations in nanotechnology and its increased use in surgical mask production together with upsurge in demand for single use of nonwoven surgical mask are predicted to make remunerative opportunities for the India surgical masks market growth within the near future. Related Project Blog: - Blog Global Market Increasing need for improved safety standard has led to the rise within the growth of the surgical mask market as success rate of surgeries largely depends on the extent of safety and precautions taken during surgeries. Surgical mask are used as a barrier to avoid cross contamination by microorganisms and are used during surgical procedures. The surgical mask is used by surgeons during procedures and other medical professionals while interacting with the patients to avoid cross contamination of microorganisms. The patient who is under treatment also must be protected against infectious agents that's set to be discharged by others within the surgery rooms. Related Projects: - Healthcare and Medical Businesses The demand within the worldwide marketplace for surgical mask has been rising on account of advancements within the field of medical surgery and diagnosis. Surgical masks are meant to guard doctors and surgeons from harmful infections and pathogens which will get suspended within the surgery room. Furthermore, the patient who is under treatment also must be shielded from infectious agents which will be discharged by others within the surgery rooms. Hence, the worldwide marketplace for surgical mask is predicted to expand at a stellar pace within the years to follow. There are multiple attempts at manufacturing improved surgical masks, and this has given an impetus to plug growth. Projects:- Project Reports & Profiles The Global Disposable Face Masks Market size is expected to reach $91.3 billion by the end of 2020, rising at a market growth of 97.4% CAGR during the forecast period (2019-2025). Disposable face masks are widely prevalent among medical professionals, industry workers, sanitation personnel, laboratory workers, police and security personnel, airport security personnel, and the general public. These masks are practically worn by anyone who opts to add an extra safety precaution of hygiene and safety in their daily routine. The global disposable face masks market includes the type of face masks that are used for covering the nose and the mouth of the wearer for providing protection against contamination, infection, protection from potential viruses as well as foreign or harmful elements in the surrounding. Books:- BOOKS & DATABASES Key Players Key players operating in the India surgical masks market such as Thea-Tex Healthcare (India) Pvt. Ltd., Venus Safety & Health Pvt. Ltd., Magnum Health and Safety Private Limited, Z Plus Disposable, Salus Products, Smilepad Hygiene India Pvt. Ltd., Cartel Healthcare Pvt. Ltd., MBL Impex Private Limited, Medicare Hygiene Limited, Mediblue Health Care Private Limited., Plasti Surge Industries Pvt. Ltd., Medline Industries Inc., Premium Health Care Disposables Private Limited, Kwalitex Healthcare Private Limited, and 3M Company Tags:- #disposablesurgicalmasks #facemask #mask #surgicalmasks #SurgicalMaskProduction #Covid19Pandemic #SurgicalMaskMarket #medicalmasks #protectionmask #SafeFaceMask #disposablemask #cottonmasks #N95Mask #KN95Mask #COVID_19 #MedicalFaceMask #MedicalMask #3PlyFaceMask #3PlyMask #3LayerFaceMask #3LayerMask #COVID19 #DetailedProjectReport #businessconsultant #feasibilityReport #NPCS #BusinessPlan #startupideas #entrepreneurindia #startupbusiness #projectreport #DetailedProjectReport #businessconsultant #BusinessPlan #feasibilityReport #NPCS
Plant capacity: -Plant & machinery: -
Working capital: -T.C.I: -
Return: 1.00%Break even: N/A
Add to Inquiry Add to Inquiry Basket

Information
  • One Lac / Lakh / Lakhs is equivalent to one hundred thousand (100,000)
  • One Crore is equivalent to ten million (10,000,000)
  • T.C.I is Total Capital Investment
  • We can modify the project capacity and project cost as per your requirement.
  • We can also prepare project report on any subject as per your requirement.
  • Caution: The project's cost, capacity and return are subject to change without any notice. Future projects may have different values of project cost, capacity or return.

Add multiple items to inquiry
Select the items and then press Add to inquiry button

Page 11 of 54 | Total 531 projects in this category
« Previous   Page 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 .... 53 54   Next »

About NIIR PROJECT CONSULTANCY SERVICES

Hide »

NIIR PROJECT CONSULTANCY SERVICES (NPCS) is a reliable name in the industrial world for offering integrated technical consultancy services. NPCS is manned by engineers, planners, specialists, financial experts, economic analysts and design specialists with extensive experience in the related industries.

Our various services are: Detailed Project Report, Business Plan for Manufacturing Plant, Start-up Ideas, Business Ideas for Entrepreneurs, Start up Business Opportunities, entrepreneurship projects, Successful Business Plan, Industry Trends, Market Research, Manufacturing Process, Machinery, Raw Materials, project report, Cost and Revenue, Pre-feasibility study for Profitable Manufacturing Business, Project Identification, Project Feasibility and Market Study, Identification of Profitable Industrial Project Opportunities, Business Opportunities, Investment Opportunities for Most Profitable Business in India, Manufacturing Business Ideas, Preparation of Project Profile, Pre-Investment and Pre-Feasibility Study, Market Research Study, Preparation of Techno-Economic Feasibility Report, Identification and Selection of Plant, Process, Equipment, General Guidance, Startup Help, Technical and Commercial Counseling for setting up new industrial project and Most Profitable Small Scale Business.

NPCS also publishes varies process technology, technical, reference, self employment and startup books, directory, business and industry database, bankable detailed project report, market research report on various industries, small scale industry and profit making business. Besides being used by manufacturers, industrialists and entrepreneurs, our publications are also used by professionals including project engineers, information services bureau, consultants and project consultancy firms as one of the input in their research.

^ Top